Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Versant Futures

- PMLiVE

Novo Nordisk to acquire cardiovascular disease specialist Cardior in deal worth over €1bn

The deal includes a candidate being evaluated in a mid-stage trial to treat heart failure patients

- PMLiVE

NeuroDerm shares positive phase 3 results for investigational Parkinson’s disease therapy

The progressive neurodegenerative disease affects around ten million people worldwide

Bayer symbol

Bayer’s non-hormonal menopause drug elinzanetant shows promise in long-term study

Vasomotor symptoms are reported by up to 80% of women during the menopausal transition

Bayer symbol

Bayer and BridgeBio enter European partnership worth up to $310m for ATTR-CM

The rare and progressive condition affects around 500,000 people worldwide

- PMLiVE

AbbVie’s Produodopa rolled out by NHS England for advanced Parkinson’s patients

The roll out follows NICE’s recommendation of the treatment in October 2023

- PMLiVE

Researchers suggest erectile dysfunction drugs could reduce risk of Alzheimer’s

The study found that men prescribed PDE5Is were 18% less likely to develop the disease

Biogen Idec building

Biogen to discontinue Alzheimer’s drug Aduhelm in favour of Eisai-partnered Leqembi

The post-marketing confirmatory study of the intravenous treatment will now be terminated

Bayer symbol

Bayer’s non-hormonal menopause drug elinzanetant shows promise in phase 3 studies

Vasomotor symptoms are estimated to affect up to 80% of menopausal women

- PMLiVE

Study suggests hearing aids could prevent onset and progression of dementia

People with severe hearing loss had an increased risk of up to 20% of developing dementia

- PMLiVE

Researchers develop new blood test to identify risk of Parkinson’s disease

The findings could help to identify people most likely to benefit from disease-modifying therapies

- PMLiVE

Study programme to investigate blocking brain inflammation in Parkinson’s patients

If successful, the findings could lead to new medicines to treat the neurological disease

- PMLiVE

Study suggests health and lifestyle factors could be linked to young-onset dementia

There are around 370,000 new cases of young-onset dementia globally every year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links